Clinical trial • Musculoskeletal

Alendronic acid (Alendronate) for Osteoporosis

Clinical trial of Alendronic acid (Alendronate) for Osteoporosis.

Overview

Trial Therapeutic Area
Musculoskeletal
Trial Disease
Osteoporosis
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
09-06-2024
First CTIS Authorization Date
22-07-2024

Trial design

Randomised, alendronate continuation versus discontinuation (comparator details: dose and schedule not specified in record).-controlled trial across 8 sites in Denmark.

Randomised
Yes
Comparator
Alendronate continuation versus discontinuation (comparator details: dose and schedule not specified in record).
Target Sample Size
1400
Trial Duration For Participant
1095

Eligibility

Recruits 1400 No vulnerable populations selected (isVulnerablePopulationSelected=false). Consent obtained from adult participants; subject information and informed consent forms for adults are provided. No assent or parental consent for minors is mentioned..

Vulnerable Population
No vulnerable populations selected (isVulnerablePopulationSelected=false). Consent obtained from adult participants; subject information and informed consent forms for adults are provided. No assent or parental consent for minors is mentioned.

Inclusion criteria

  • {"criterion_text":"-Female, Postmenopausal, Current treatment with Alendronate, Alendronate treatment >3 år AND no previous major osteoporotic fracture OR Alendronate treatment >5 år AND latest major osteporotic fracture > 3 years ago, ** Major osteoprotic fracture is defined as low energy fractures in hip, proximal humerus, distal radius, or vertebral fracture"}

Exclusion criteria

  • {"criterion_text":"-T-score < - 3,5 in hip (total hip or femoral neck) or lumbar spine, Treatment with systemic glucocorticoids for more than two weeks, ongoing or within 12 months, Uncontrolled inflammatory disease, Active malignancy, eGFR < 40 mL/min, Atypical femur fracture (ever), OsteoNecrosis of the Jaw (active), Unable to give inform consent"}

Endpoints

Primary endpoints

  • {"endpoint_text":"-Incidence of fragility fractures during the study periode","definition_or_measurement_approach":"Not further defined in the record; stated as incidence of fragility fractures during the study period."}

Secondary endpoints

  • {"endpoint_text":"-Changes in BMD spine and hip from inclusion to study end (3 years), Changes in Bone Turnover Markers over the study period (CTX and P1NP),Proportion of patients meeting restart criteria ,Adverse events.","definition_or_measurement_approach":"Changes in BMD spine and hip measured from inclusion to study end (3 years); Bone turnover markers (CTX and P1NP) measured over study period; proportion meeting restart criteria (criteria not specified here); adverse events recorded (details not specified here)."}

Recruitment

Planned Sample Size
1400
Recruitment Window Months
60
Consent Approach
Informed consent obtained from participants. Multiple subject information and informed consent forms for adults are provided (documents listed in CTIS). Participants are adults (postmenopausal females); no assent or parental consent arrangements are mentioned.

Geography

Total Number Of Sites
8
Total Number Of Participants
1400

Denmark

Earliest CTIS Part Ii Submission Date
15-07-2024
Latest Decision Or Authorization Date
08-08-2025
Processing Time Days
389
Number Of Sites
8
Number Of Participants
1400

Sites

Site Name
Copenhagen University Hospital
Department Name
Endocrinology
Principal Investigator Name
Jakob Præst Holm
Principal Investigator Email
jakob.praest.holm.01@regionh.dk
Contact Person Name
Jakob Præst Holm
Site Name
Nordsjaellands Hospital
Department Name
Endocrinology
Principal Investigator Name
Louise Tjelum
Principal Investigator Email
louise.tjelum@regionh.dk
Contact Person Name
Louise Tjelum
Contact Person Email
louise.tjelum@regionh.dk
Site Name
Esbjerg Og Grindsted Sygehus
Department Name
Endocrinology
Principal Investigator Name
Jeppe Gram
Principal Investigator Email
svs-forskning@rsyd.dk
Contact Person Name
Jeppe Gram
Contact Person Email
svs-forskning@rsyd.dk
Site Name
Odense University Hospital
Department Name
Endocrinology
Principal Investigator Name
Pernille Hermann
Principal Investigator Email
pernille.hermann@rsyd.dk
Contact Person Name
Pernille Hermann
Contact Person Email
pernille.hermann@rsyd.dk
Site Name
Bispebjerg Hospital
Department Name
endocrinology
Principal Investigator Name
pia eiken
Principal Investigator Email
pia.eiken.01@regionh.dk
Contact Person Name
pia eiken
Contact Person Email
pia.eiken.01@regionh.dk
Site Name
Region Syddanmark
Department Name
Internal Medicine
Principal Investigator Name
Frans Hjelm Brandt Kristensen
Principal Investigator Email
FBK@rsyd.dk
Contact Person Name
Frans Hjelm Brandt Kristensen
Contact Person Email
FBK@rsyd.dk
Site Name
Aalborg University Hospital
Department Name
endocrinology
Principal Investigator Name
peter vestergaard
Principal Investigator Email
p.vestergaard@rn.dk
Contact Person Name
peter vestergaard
Contact Person Email
p.vestergaard@rn.dk
Site Name
Hvidovre Hospital
Department Name
Endocrinology
Principal Investigator Name
Jens-Erik Bech Jensen
Principal Investigator Email
jens-erik.beck-jensen@regionh.dk
Contact Person Name
Jens-Erik Bech Jensen

Sponsor

Primary sponsor

Full Name
Odense University Hospital
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Denmark

Third parties

  • {"country":"Denmark","full_name":"Odense University Hospital","duties_or_roles":"sponsorDuties codes: 1, 8","organisation_type":"Hospital/Clinic/Other health care facility"}

Investigational products

Investigational Product Name
ALENDRONIC ACID
Active Substance
Alendronic acid (Alendronate)
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
oral
Maximum Dose
10 mg (maxDailyDoseAmount = 10 mg)
Investigational Product Name
TETRACYCLINE
Active Substance
Tetracycline hydrochloride
Modality
Small molecule
Routes Of Administration
ORAL
Route
oral
Maximum Dose
1000 mg (maxDailyDoseAmount = 1000 mg)

Related trials

Other published trials that may interest you.